Preclinical Rett Syndrome Studies
Rett syndrome is a neurodevelopmental disorder caused by mutations in the X-linked methyl CpG binding protein 2 (Mecp2) gene. Primarily...
PsychoGenics Chief Innovation Officer Honored for Scientific Excellence
PsychoGenics announces that Daniela Brunner Ph.D., Chief Innovation Officer, was named the recipient of Great Minds in STEMTM (GMiS) Scientist of...
Preclinical Rare CNS Disorders Research
PsychoGenics offers specialized preclinical research services tailored to rare CNS disorders to drive your program forward. Leveraging our translational research...
Sleep & Seizure Disorders
At PsychoGenics, we provide expert preclinical epilepsy and seizure disorder studies and services to help you discover your breakthrough therapy. Our...
Dani Brunner, Ph.D.
Dr. Brunner received her Ph.D. at Cambridge University (U.K.) and postdoctoral training at Columbia University (USA). She joined PsychoGenics in...
PsychoGenics Further Strengthens its Leadership Team, Adding Three Senior Executives
Daniela Brunner, Chief Innovation Officer; Geoffrey Varty, Executive Vice President, Research Operations; and Leslie Street, Vice President, Medicinal Chemistry PsychoGenics Inc....
PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day
Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC...
Preclinical Gaucher Disease Studies
Gaucher disease, a rare genetic disorder, is caused by mutations in the GBA gene, which encodes the enzyme glucocerebrosidase (also...
Preclinical Dravet Syndrome Studies
PsychoGenics is highly experienced in preclinical studies of Dravet syndrome, a rare and debilitating genetic disorder characterized by severe and...
Preclinical Epilepsy Studies
PsychoGenics has exceptional capabilities and experience in preclinical epilepsy research. This neurological disorder is characterized by recurrent and unpredictable seizures,...